COVID-19 Updates | Jubilant Life Sciences Among Companies to Manufacture & Sell Remdesivir in India
- 3 years ago
Jubilant Life Sciences Limited has entered into a “non-exclusive licensing agreement” with Gilead Sciences the maker of the remdesivir drug to manufacture and sell Remdesivir in India along with 126 other countries. Earlier this month, remdesivir was given Emergency Use Authorization by the USFDA. Recent studies have shown that patients receiving remdesivir had a numerically faster time to clinical improvement. The drug remains investigational but is being seen as a potential treatment for COVID -19. As per the latest update on the Gilead Sciences website, five generic pharmaceutical manufacturers based in India and Pakistan to further expand the supply of remdesivir. The agreements allow the companies – Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan – to manufacture remdesivir for distribution in 127 countries.
Like our work? Click here to support The Wire: https://thewire.in/support
The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
Facebook
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
Twitter
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
Instagram
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!
Like our work? Click here to support The Wire: https://thewire.in/support
The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!